Rigel Pharmaceuticals (NASDAQ: RIGL) is 92.28% higher on its value in year-to-date trading and has touched a low of $7.48 and a high of $29.82 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RIGL stock was last observed hovering at around $26.70 in the last trading session, with the day’s gains setting it 1.18%.
Currently trading at $27.88, the stock is 25.91% and 55.04% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.21 million and changing 4.42% at the moment leaves the stock 112.45% off its SMA200. RIGL registered 173.33% gain for a year compared to 6-month gain of 197.70%. The firm has a 50-day simple moving average (SMA 50) of $17.6978 and a 200-day simple moving average (SMA200) of $13.0389.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 94.42% loss in the last 1 month and extending the period to 3 months gives it a 105.76%, and is 14.69% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.12% over the week and 9.17% over the month.
Rigel Pharmaceuticals (RIGL) has around 147 employees, a market worth around $491.11M and $157.47M in sales. Current P/E ratio is 128.72 and Fwd P/E is 28.53. Profit margin for the company is 2.46%. Distance from 52-week low is 272.51% and -6.51% from its 52-week high. The company has generated returns on investments over the last 12 months (8.60%).
The EPS is expected to grow by 120.53% this year
129.0 institutions hold shares in Rigel Pharmaceuticals (RIGL), with institutional investors hold 69.58% of the company’s shares. The shares outstanding are 17.48M, and float is at 17.27M with Short Float at 2.68%. Institutions hold 68.06% of the Float.
The top institutional shareholder in the company is BARCLAYS PLC with over 10573.0 shares valued at $88000.0. The investor’s holdings represent 0.006 of the RIGL Shares outstanding. As of 2024-06-30, the second largest holder is IFP ADVISORS, INC with 1000.0 shares valued at $807.0 to account for 0.0006 of the shares outstanding. The other top investors are RONALD BLUE TRUST, INC. which holds 500.0 shares representing 0.0003 and valued at over $740.0, while MATHER GROUP, LLC. holds 0.0003 of the shares totaling 450.0 with a market value of $666.0.
Rigel Pharmaceuticals (RIGL) Insider Activity
The most recent transaction is an insider sale by Santos David A, the company’s EVP, Chief Commercial Officer. SEC filings show that Santos David A sold 8,918 shares of the company’s common stock on Feb 05 ’24 at a price of $1.14 per share for a total of $10167.0. Following the sale, the insider now owns 0.35 million shares.
Rigel Pharmaceuticals disclosed in a document filed with the SEC on Feb 02 ’24 that Santos David A (EVP, Chief Commercial Officer) sold a total of 5,601 shares of the company’s common stock. The trade occurred on Feb 02 ’24 and was made at $1.13 per share for $6329.0. Following the transaction, the insider now directly holds 0.36 million shares of the RIGL stock.
Still, SEC filings show that on Feb 05 ’24, Schorno Dean L (EVP & Chief Financial Officer) disposed off 7,027 shares at an average price of $1.14 for $8011.0. The insider now directly holds 402,891 shares of Rigel Pharmaceuticals (RIGL).
